Edaravone

Edaravone
Clinical data
Trade names	Radicava, others
Other names	MCI-186
AHFS/Drugs.com	Monograph
MedlinePlus	a617027
License data	US DailyMed: Edaravone;
Pregnancy; category	AU: B3;
Routes of; administration	Intravenous, by mouth
ATC code	N07XX14 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; In general: ℞ (Prescription only);
Identifiers
	IUPAC name 5-methyl-2-phenyl-4H-pyrazol-3-one;
CAS Number	89-25-8 ;
PubChem CID	4021;
DrugBank	DB12243 ;
ChemSpider	3881 ;
UNII	S798V6YJRP;
KEGG	D01552 ;
ChEBI	CHEBI:31530 ;
ChEMBL	ChEMBL290916 ;
PDB ligand	W1P (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID9021130 ;
ECHA InfoCard	100.001.719
Chemical and physical data
Formula	C10H10N2O
Molar mass	174.203 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1N(/N=C(\C1)C)c2ccccc2;
	InChI InChI=1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3 ; Key:QELUYTUMUWHWMC-UHFFFAOYSA-N ;
	(verify)

Edaravone, sold under the brand name Radicava among others, is a medication used to treat stroke and amyotrophic lateral sclerosis (ALS).^[4]^[5] It is given by intravenous infusion^[4] and by mouth.^[4]^[6]

The mechanism by which edaravone might be effective is unknown.^[4] The medication is known to be an antioxidant, and oxidative stress has been hypothesized to be part of the process that kills neurons in people with ALS and in stroke victims.^[7]

The most common side effects include bruising (contusions), problems walking (gait disturbances), and headaches.^[6]

The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.^[8]

^ ^a ^b "Radicava". Therapeutic Goods Administration (TGA). 24 February 2023. Archived from the original on 24 February 2023. Retrieved 7 April 2023.
^ "Radicava edaravone 30 mg/20 mL concentrated injection ampoule (375455)". Therapeutic Goods Administration (TGA). 16 February 2023. Archived from the original on 8 April 2023. Retrieved 7 April 2023.
^ "Regulatory Decision Summary for Radicava". 23 October 2014. Archived from the original on 7 June 2022. Retrieved 7 June 2022.
^ ^a ^b ^c ^d ^e "Radicava- edaravone injection Radicava ORS- edaravone kit". DailyMed. 12 May 2022. Archived from the original on 27 January 2022. Retrieved 27 May 2022.
^ Bailly C, Hecquet PE, Kouach M, Thuru X, Goossens JF (May 2020). "Chemical reactivity and uses of 1-phenyl-3-methyl-5-pyrazolone (PMP), also known as edaravone". Bioorganic & Medicinal Chemistry. 28 (10) 115463: 115463. doi:10.1016/j.bmc.2020.115463. PMID 32241621. S2CID 214766793.
^ ^a ^b "FDA Approves Oral Form of ALS Treatment". U.S. Food and Drug Administration (FDA). 12 May 2022. Archived from the original on 12 May 2022. Retrieved 12 May 2022. This article incorporates text from this source, which is in the public domain.
^ Cite error: The named reference Petrov_2017 was invoked but never defined (see the help page).
^ New Drug Therapy Approvals 2017. U.S. Food and Drug Administration (FDA) (Report). January 2018. Archived from the original (PDF) on 23 October 2020. Retrieved 16 September 2020.

[Radicava_APMDS-1] "Radicava". Therapeutic Goods Administration (TGA). 24 February 2023. Archived from the original on 24 February 2023. Retrieved 7 April 2023.

[2] "Radicava edaravone 30 mg/20 mL concentrated injection ampoule (375455)". Therapeutic Goods Administration (TGA). 16 February 2023. Archived from the original on 8 April 2023. Retrieved 7 April 2023.

[3] "Regulatory Decision Summary for Radicava". 23 October 2014. Archived from the original on 7 June 2022. Retrieved 7 June 2022.

[Radicava_FDA_label-4] "Radicava- edaravone injection Radicava ORS- edaravone kit". DailyMed. 12 May 2022. Archived from the original on 27 January 2022. Retrieved 27 May 2022.

[5] Bailly C, Hecquet PE, Kouach M, Thuru X, Goossens JF (May 2020). "Chemical reactivity and uses of 1-phenyl-3-methyl-5-pyrazolone (PMP), also known as edaravone". Bioorganic & Medicinal Chemistry. 28 (10) 115463: 115463. doi:10.1016/j.bmc.2020.115463. PMID 32241621. S2CID 214766793.

[FDA_PR_20220512-6] "FDA Approves Oral Form of ALS Treatment". U.S. Food and Drug Administration (FDA). 12 May 2022. Archived from the original on 12 May 2022. Retrieved 12 May 2022. This article incorporates text from this source, which is in the public domain.

[Petrov_2017-7] Cite error: The named reference Petrov_2017 was invoked but never defined (see the help page).

[8] New Drug Therapy Approvals 2017. U.S. Food and Drug Administration (FDA) (Report). January 2018. Archived from the original (PDF) on 23 October 2020. Retrieved 16 September 2020.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]